Skip to main content
. 2026 Oct 14;3(1):e20260040. doi: 10.70962/jhi.20260040

Figure 8.

Multiple line graphs depict changes in T-cell subsets over time. Panel A: A line graph shows the mean percentage of CD4 positive T cells over time. Panel B: A line graph shows the mean percentage of CD8 positive T cells over time. Panel C: A line graph shows the mean percentage of naive CD4 positive T cells over time. Panel D: A line graph shows the mean percentage of naive CD8 positive T cells over time. Panel E: A line graph shows the mean percentage of programmed cell death protein 1 positive CD4 positive T cells over time. Panel F: A line graph shows the mean percentage of programmed cell death protein 1 positive CD8 positive T cells over time. Panel G: A line graph shows the mean percentage of senescent CD4 positive T cells over time. Panel H: A line graph shows the mean percentage of senescent CD8 positive T cells over time. All panels show Baseline, ED84, ED168, and ED252 on the x-axis and percentage of the indicated T-cell subset on the y-axis, comparing the overall cohort, previous leniolisib, previous placebo, and new to open-label extension groups, with gray boxes indicating reference ranges.

Sustained changes in T cell subsets. (A and B) (A) Mean CD4+ and (B) CD8+ T cell percentages over time. (C and D) (C) Mean naïve CD4+ and (D) naïve CD8+ T cell percentages (CD45RA+CD62L+) over time. (E and F) (E) Mean PD-1+CD4+ and (F) PD-1+CD8+ T cell percentages over time. (G and H) (G) Mean senescent (CD57+) CD4+ and (H) senescent CD8+ T cell percentages over time. Patients are grouped into the following categories: overall (total cohort), previous leniolisib (received leniolisib prior to OLE), previous placebo (received placebo prior to OLE), and new to OLE (were not enrolled in prior leniolisib trials). Gray boxes indicate reference ranges, which were obtained from either literature (panels A–F) or personal communication (panels G and H; Manish Butte).